Comparative Pharmacology
Head-to-head clinical analysis: BAMATE versus BUSPIRONE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAMATE versus BUSPIRONE HYDROCHLORIDE.
BAMATE vs BUSPIRONE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The mechanism of action of BAMATE is not well established; it is thought to involve inhibition of monoamine oxidase (MAO) with preferential inhibition of MAO-B at low doses, leading to increased concentrations of dopamine and other biogenic amines in the brain.
Partial agonist at serotonin 5-HT1A receptors, primarily in the raphe nuclei and hippocampus; also exhibits antagonist properties at presynaptic 5-HT1A autoreceptors and postsynaptic 5-HT1A receptors, resulting in decreased serotonergic activity. Additionally, it has moderate affinity for dopamine D2 receptors (antagonist) and alpha2-adrenergic receptors.
400 mg orally twice daily
Initial dose: 7.5 mg orally twice daily; may increase by 2.5-5 mg every 2-3 days to a target dose of 15-30 mg/day in divided doses (2-3 times daily). Maximum dose: 60 mg/day divided twice daily.
None Documented
None Documented
Clinical Note
moderateFelbamate + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Felbamate."
Clinical Note
moderateMeprobamate + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Meprobamate is combined with Fluticasone propionate."
Clinical Note
moderateMeprobamate + Haloperidol
"The risk or severity of adverse effects can be increased when Meprobamate is combined with Haloperidol."
Clinical Note
moderateTerminal elimination half-life is 2-4 hours in healthy adults. This short half-life necessitates frequent dosing to maintain therapeutic levels.
2-3 hours terminal half-life; clinical context: requires multiple daily dosing (3 times daily) due to short half-life; no active metabolites prolonging effect.
BAMATE is primarily excreted renally as unchanged drug (approximately 60-70%) and as glucuronide conjugates (20-30%). Fecal elimination accounts for less than 10%.
Renal: 29-63% (as metabolites; <1% unchanged); Fecal: 18-38%; Hepatic metabolism primarily via CYP3A4; total clearance 1.5-3.5 L/h/kg.
Category C
Category A/B
Anxiolytic
Anxiolytic
Felbamate + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Felbamate."